Indexes and factors related to adherence to pharmacological treatment in patients with Juvenile Idiopathic Arthritis




Adherence; Drug Therapy; Juvenile idiopathic arthritis.


Juvenile idiopathic arthritis (JIA) is a form of chronic arthritis that begins before age 16. Environmental, socioeconomic and therapeutic factors can influence adherence to treatment, severity and perception of the disease. The objective was to identify adherence rates and factors that hinder treatment in patients with JIA in Brazil and worldwide. This is a literature review, conducted from 1999 to 2020, based on the search for publications in the following databases: PubMed, LILACS, Scielo and Science direct. After applying the inclusion and exclusion criteria, 11 of the 189 publications remained. Of the 11 selected studies on adherence, 4 were in the United States, 3 in Canada, 1 in Spain and 4 in Brazil. With regard to adherence, the United States had a maximum value of 82%. Brazil, on the other hand, presented a maximum value of 76%. The selected studies also revealed that the main barrier to adherence in patients with JIA is fear of the consequences of using the therapy. In Brazil, other factors, such as: high cost, difficult access to health services, specialists and medication, as well as geographic distance, interfere with adherence. Brazil presents treatment adherence values similar to those found in developed countries, however, there are still local and regional disparities regarding adherence. These disparities can be explained in part by the difficulty in accessing both health services and medication and the abandonment of pharmacotherapeutic follow-up.


Adriano, L. S., de França Fonteles, M. M., de Fátima Menezes Azevedo, M., Beserra, M. P. & Romero, N. R. (2017). Medication adherence in patients with juvenile idiopathic arthritis. Rev Bras Reumatol Engl. 57(1), 23-29.

Agoston, A.M., Gray, L.S., & Logan, D.E. (2016). Pain in School: Patterns of Pain-Related School Impairment among Adolescents with Primary Pain Conditions, Juvenile Idiopathic Arthritis Pain, and Pain-Free Peers. Children. 3, 39.

Angeles-Han, S. T., Ringold, S., Beukelman, T., Lovell, D., Cuello, C. A., Becker, M. L., Colbert, R. A., Feldman, B. M., Holland, G. N., Ferguson, P. J., Gewanter, H., Guzman, J., Horonjeff, J., Nigrovic, P. A., Ombrello, M. J., Passo, M. H., Stoll, M. L., Rabinovich, C. E., Sen, H. N., Schneider, R., & Reston, J. (2019). American College of Rheumatology /Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Care Res (Hoboken). 71(6), 703-716.

April, K.T., Feldman, D.E., Platt, R.W., & Duffy, C.M. (2006). Comparison between children with juvenile idiopathic arthritis and their parents concerning perceived treatment adherence. Arthritis Rheum, 55, 558–563.

April, K.T., Feldman, D.E., Zunzunegui, M.V., & Duffy, C.M. (2008). Association between perceived treatment adherence and health-related quality of life in children with juvenile idiopathic arthritis: perspectives of both parents and children. Patient Prefer Adherence. 2(2), 121-128.

Bernatsky S, et al. Economic impact of juvenile idiopathic arthritis. Arthritis Rheum. 2007,57: 4448.

Berthold, E., Månsson, B., & Kahn, R. (2019). Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther, 21(1), 218.

BRASIL, MINISTÉRIO DA SAÚDE. Portaria de Consolidação nº 2, de 28 de setembro de 2017. Consolidação das normas sobre as políticas nacionais de saúde do Sistema Único de Saúde. Diário Oficial do Distrito Federal, Brasília, DF, n. 190, seção 1 – suplemento – p.61, 2017.

BRASIL, MINISTÉRIO DA SAÚDE. Portaria Conjunta nº 16, de 03 de setembro de 2021. Aprova o Protocolo Clínico Diretrizes Terapêuticas da Artrite Reumatoide e da Artrite idiopática Juvenil. Diário Oficial do Distrito Federal, Brasília, DF, n. 172, seção 1, p.107, 2021.

Bugni, V. M., Ozaki, L. S., Okamoto, K. Y., Barbosa, C. M., Hilário, M. O., Len, C. A., & Terreri, M. T. (2012). Factors associated with adherence to treatment in children and adolescents with chronic rheumatic diseases. J Pediatr (Rio J), 88:483-8.

Cardoso, G. da S., Sousa Neto, B. P. de., Magalhães, N. A., Cardoso, L. da S., Costa, G. O. P. da, Ribeiro, A. M. N., Jatobá, D. N. V., Mariano, S. C. B., Cruz, F. C. da., Pinheiro, D. M., Castro, M. C. de O., Paz, M. I., Araújo, D. S. de., & Jansen, R. C. S. (2021). Factors that interfere with adherence to pharmacological treatment in hypertensive elderly. Research, Society and Development. 10(2), e17510212352, 2021.

Cobra, JF. (2020a). Os imunobiológicos e a prática da “reumatologia baseada em valor”.

Cobra, JF. (2020b). Reumatologistas ainda são poucos e raros no Brasil.

Cutler, R.L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018). Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open, 8(1), e016982.

Degotardi, P.J., Revenson, T.A., & Ilowite, N.T. (1999). Family-level coping in juvenile rheumatoid arthritis: assessing the utility of a quantitative family interview. Arthritis Care Res. 12, 314–324.

Ellis, J.A., Munro, J.E., & Ponsonby, A.L. (2010). Possible environmental determinants of juvenile idiopathic arthritis. Rheumatology (Oxford). 49(3), 411-425.

Favier, L. A., Taylor, J., Loiselle Rich, K., Jones, K. B., Vora, S. S., Harris, J. G., Gottlieb, B. S., Robbins, L., Lai, J. T., Lee, T., Kohlheim, M., Gill, J., Bouslaugh, L., Young, A., Griffin, N., Morgan, E. M., & Modi, A. C. (2018). Barriers to Adherence in Juvenile Idiopathic Arthritis: A Multicenter Collaborative Experience and Preliminary Results. J Rheumatol. 45(5), 690-696.

Feldman, D.E., De Civita, M., Dobkin, P.L., Malleson, P.N., Meshefedjian, G., & Duffy, C.M. (2007). Effects of adherence to treatment on short-term outcomes in children with juvenile idiopathic arthritis. Arthritis Rheum. 57, 905-912.

Giancane, G., Muratore, V., Marzetti, V., Quilis, N., Benavente, B.S., Bagnasco, F., Alongi, A., Civino, A., Quartulli, L., Consolaro, A., & Ravelli, A. (2019). Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Res Ther. 21(1):168.

Goettel, A.M., DeClercq, J., Choi, L., Graham, T.B., & Mitchell, A.A. (2021). Efficacy and Safety of Abatacept, Adalimumab, and Etanercept in Pediatric Patients With Juvenile Idiopathic Arthritis. J Pediatr Pharmacol Ther. 26(2):157-162.

Helmick, C.G., Felson, D.T., Lawrence, R.C., Gabriel, S., Hirsch, R., Kwoh, C.K., Liang, M.H., Kremers, H.M., Mayes, M.D., Merkel, P.A., Pillemer, S.R., Reveille, J.D., & Stone, J.H. (2008). National Arthritis Data Workgroup.Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 58(1), 15-25.

Krause, M.L., Zamora-Legoff, J.A., Crowson, C.S., Muskardin, T.W., Mason, T., & Matteson, E.L. (2017). Population-based study of outcomes of patients with juvenile idiopathic arthritis (JIA) compared to non-JIA subjects. Semin Arthritis Rheum. 46(4):439-443.

Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis JP, et al. The PRISMA Statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. (Em linha) BMJ, 21,339:b2700, 2009.

Marshall, A., Gupta, K., Pazirandeh, M., Bonafede, M., & McMorrow, D. (2019). Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis. Clinicoecon Outcomes Res. 31(11), 361-371.

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D.G. (2009). PRISMA Group.Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. PLoS Medicine, 6(7):e1000097, 2009.

Nieto-González, J.C., Trives-Folguera, L., Melgarejo-Ortuño, A., Ais, A., Serrano-Benavente, B., Sanjurjo, M., Álvaro-Gracia, J.M., & Sáez, I.M. (2021). Persistence and adherence to biologic therapies in juvenile idiopathic arthritis. Sci Rep. 11(1):16195.

Pasma, A., Schenk, C. V., Timman, R., Busschbach, J. J., van den Bemt, B. J., Molenaar, E., van der Laan, W. H., Schrauwen, S., Van't Spijker, A., & Hazes, J. M. (2015). Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Res Ther. 17:281.

Pelajo, C.F., Sgarlat, C.M., Lopez-Benitez, J.M., Oliveira, S.K., Rodrigues, M.C., Sztajnbok, F.R., Diniz, C.C., & Miller, L.C. (2012). Adherence to methotrexate in juvenile idiopathic arthritis. Rheumatol Int. 32(2), 497-500.

Rapoff, M.A., Belmont, J.M., Lindsley, C.B., & Olson, N.Y. (2005). Electronically monitored adherence to medications by newly diagnosed patients with juvenile rheumatoid arthritis. Arthritis Rheum. 53:905–910

Rasu, R. S., Cline, S. K., Shaw, J. W., Hayes, O., Agbor Bawa, W., & Cifaldi, M. A. (2015). Impact of JIA on Parents’ Work Absences. Rheumatology.

Ringold, S., Grant, S., Girdish, C., Wallace, C.A., & Sullivan, S.D. (2013). Methotrexate and injectable tumor necrosis factor-alpha inhibitor adherence and persistence in children with rheumatic diseases. J Rheumatol. 40:80–86.

Rocha, F.A.C., Landim, J.I.V.D., Aguiar, M.G., Accioly, J.P.E., Lechiu, C.N., Costa, L.H.A., Júnior, C.N.R., da Rocha, L.N., & Rocha, H.A.L. (2019). Evaluation of disease activity in a low-income juvenile idiopathic arthritis cohort. Rheumatol Int. 39(1), 67-71.

Schinzel, V., da Silva, S.G.L., Terreri, M.T., & Len, C.A. (2019). Prevalence of juvenile idiopathic arthritis in schoolchildren from the city of São Paulo, the largest city in Latin America. Adv Rheumatol. 59(1), 32.

Silva, V.B.M.E., Okamoto, K.Y.K., Ozaki, L.D.S., Len, C.A., & Terreri, M.T.S.E.L.R.A. (2019). Early detection of poor adherence to treatment of pediatric rheumatic diseases:pediatric rheumatology adherence questionnaire-A pilot study. Rev Paul Pediatr. 37(2), 149-155.

Thierry, S., Fautrel, B., Lemelle, I., & Guillemin, F. (2014). Prevalence and incidence of juvenile idiopathic arthritis: a systematic review. Joint Bone Spine. 81(2), 112-117.

Torres, P. (2018). Ministério da Saúde mantém 8 medicamentos biológicos para artrite reumatoide no SUS.

Valer, P. (2022). Renda média do brasileiro chega aos R$ 1.353, menor valor em 10 anos.

Verstappen, S.M., Cobb, J., Foster, H.E., Fu, B., Baildam, E., Wedderburn, L.R., Davidson, J.E., Ioannou, J., Chieng, A., Hyrich, K.L., & Thomson, W. (2015). The association between low socioeconomic status with high physical limitations and low illness self-perception in patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study. Arthritis Care Res (Hoboken). 67(3), 382-389.

Yamashita, E., Terreri, M. T., Hilário, M. O., & Len, C. A. (2013). Prevalência da artrite idiopática juvenil em crianças com idades entre 6 e 12 anos na cidade de Embu das Artes, SP. Rev BrasReumatol. 53(6), 542 –545.



How to Cite

PINHO, L. L. de .; RABELO, A. M. F. .; RABELO, M. W. F. .; MONTEIRO, D. L. M. .; MOREIRA, M. C. C. .; RODRIGUES, L. K. de N.; LINARD, W. M. .; LEITE, A. C. R. de M. .; MELO, A. T. de .; NUNES, R. de M. Indexes and factors related to adherence to pharmacological treatment in patients with Juvenile Idiopathic Arthritis. Research, Society and Development, [S. l.], v. 12, n. 1, p. e12912139624, 2023. DOI: 10.33448/rsd-v12i1.39624. Disponível em: Acesso em: 3 feb. 2023.



Health Sciences